Molecular studies characterized
TES as tumor suppressor gene and reported its downregulation in many human malignancies [
1‐
3,
6‐
8,
20]. In 2007 Boëda et al. presented for the first time interaction between LIM3 domain of testin protein and Mena protein which is key modulator of cellular migration [
18]. Moreover, it was shown, that decreased expression of testin protein increased cell motility, decreased cell-cell contact and therefore have potential to be a marker of cancer metastasis [
4,
21,
22].
TES encodes testin protein containing a PET domain at the NH2- terminus which is involved in actin stress fibers targeting, and three LIM ((lin-1, ils-1 and mec-3) domains (LIM1, LIM2, LIM3) at the COOH-terminus. One LIM domain contain loosely conserved cysteine-rich consensus sequence including two separate zinc fingers-F1. They are separated from each other by SPACER.
Cancers are the only investigated diseases with
TES gene disruptions. It is silencing promotes cell proliferation, invasiveness ability and angiogenesis [
23,
24]. Important ways of
TES inactivation are mechanisms of loss of heterozygosity (LOH) and hypermethylation (HMT). In LOH one or two alleles of the same gene are lost, whereas in HMT occurs abnormal DNA methylation which may inactivate suppressor genes. This phenomena were described in almost every type of cancer. Predominantly, in performed studies decreased
TES gene expression associated with HMT of CpG islands nor LOH of chromosome 7q31 was found [
3,
19,
25]. In addition, methylation of
TES promoter region was described in various tumor types. Tobias et al. showed methylation of the CpG islands at the 5′ end in many types of tested tumor-derived cell lines [
26]. Tatarelli et al. found fully methylated
TES promoter in 1/10 breast, 1/8 pancreatic and 9/18 leukemia cell lines [
19]. According to Ma et al. methylation of CpG in the
TES promoter inactivate gene. Moreover, it was revealed that treatment with 5-aza-2’deoxycytidine (DAC), inhibitor of DNA methyltransferase activity, switched completely methylated
TES promoter into partially or even fully unmethylated region in gastric cancer cell lines [
3]. Upregulation of
TES gene expression after treatment with DAC in glioblastoma cells confirmed that HMT play significant role in
TES regulation, being responsible for gene silencing [
27]. Only one study presented contrary results. Han et al. indicated overexpression of
TES in GTL-16 gastric cancer cell line [
28]. High frequency of LOH was found at 7q31 region in primary gastric cancer, they identified D7S486 to be the most frequent LOH locus [
3]. As it was anticipated, there is an evidence presence of LOH in 7q31.2 in many types of neoplasms, e.g. ovary, breast, colorectal, gastric, head and neck, prostate, thyroid, pancreatic and kidney cancer as well in leukemias [
29‐
37]. Ma et al. presented correlation between LOH presence and lack of testin protein expression in gastric cancer [
1,
3]. Results are unequivocal as Chene et al. did not disclose such correlations in prostate cancer [
4].